Cardio Flow
Cardio Flow is a U.S. medical device company that develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system for treating peripheral artery disease (PAD) in hospitals, ASCs, and office-based labs.
- Company typePrivate
- Founded2014
- HeadquartersSaint Paul, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cardio Flow does
Cardio Flow, Inc. is a privately held, commercial-stage medical device company headquartered in St. Paul, Minnesota (with a physical office in Blaine, MN), founded in 2014. The company develops, manufactures, and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a proprietary spiral geometry leveraging angular momentum physics to sand away plaque blockages in peripheral arteries. The platform treats vessels from 2 mm to 8 mm in diameter with a single device and is offered with multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, 6 Fr 5-sphere), both pneumatically and electrically powered user handles, and a control module and tubing set. The portfolio also includes the FDA-cleared FreedomFlow Peripheral Guidewire.
The company received FDA 510(k) clearance for the atherectomy platform in October 2023 and completed its first commercial cases the same month at Cardiovascular Institute of the South. Cardio Flow generates revenue through direct hardware sales of single-use catheters, driveshafts, guidewires, and reusable handle/power-supply components. It goes to market exclusively in the United States via a direct field sales force targeting interventional cardiologists, interventional radiologists, and vascular surgeons practicing in hospitals, ambulatory surgery centers (ASCs), and office-based labs (OBLs). Key customers include CIS and Advanced Cardiac & Vascular Centers for Amputation Prevention, the latter led by Cardio Flow's own Chief Medical Officer Dr. Jihad Mustapha. The leadership team includes multiple former executives of Cardiovascular Systems, Inc. (now Abbott), including co-founder Gary Petrucci and former CEO Michael Kallok, who bring deep atherectomy domain and IP expertise (17+ U.S. patents attributable to Kallok).
Cardio Flow firmographics
Firmographics- Name
- Cardio Flow
- Legal name
- Cardio Flow, Inc.
- Website
- https://cardioflow.net
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cardio Flow is a U.S. medical device company that develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system for treating peripheral artery disease (PAD) in hospitals, ASCs, and office-based labs.
- Ownership category
- akta.pro rank
Cardio Flow industry classification
Industry- Product category
- Peripheral Vascular Medical Devices
- akta.pro primary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
- akta.pro secondary industry
- Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)
Keywords
Where Cardio Flow is headquartered
LocationHeadquarters
- HQ city
- Saint Paul
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cardio Flow business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- FreedomFlow Orbital Atherectomy Platform Sales: Cardio Flow generates revenue through the sale of its FreedomFlow atherectomy platform products, including catheters, driveshafts (3-sphere and 5-sphere variants in 5 Fr and 6 Fr sizes), control modules, tubing sets, user handles (pneumatic and electric), and peripheral guidewires. The platform is designed for single-device use treating multiple blockages.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Cardio Flow product offering
Product offeringCore offering
Cardio Flow develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry leveraging angular momentum physics to treat peripheral artery disease in vessels from 2 mm to 8 mm in diameter. The platform includes multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere), pneumatic and electric-powered user handles, a control module, and the complementary FreedomFlow Peripheral Guidewire, targeting hospitals, ambulatory surgery centers, and office-based labs.
Product overview
Cardio Flow is a commercial-stage medical device company that develops minimally invasive peripheral vascular products for treating Peripheral Artery Disease (PAD). The company's product portfolio centers on the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry powered by angular momentum to sand away plaque blockages. The platform includes multiple driveshaft options (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere) treating vessels from 2 mm to 8 mm in diameter, along with both pneumatic and electric-powered user handles and a control module. Complementing the atherectomy platform is the FreedomFlow Peripheral Guidewire, a stainless steel core-to-tip guidewire with silicone coating that received FDA clearance in June 2022. All products are designed, developed, and manufactured in the USA (Minnesota).
Differentiator
Problem solved
Functional benefit
Brands
- FreedomFlow: FreedomFlow is an orbital atherectomy platform for treating peripheral artery disease (PAD). The platform uses diamond-coated spheres in a spiral geometry to clear plaque blockages in peripheral arteries, treating vessels from 2mm to 8mm in diameter.
Products and services
- FreedomFlow Orbital Atherectomy Platform Catheter-based orbital atherectomy platform for treating peripheral artery disease (PAD) in hospitals, ambulatory surgery centers, and office-based labs. Uses diamond-coated spheres in a spiral geometry that creates a rotational vortex to sand away plaque blockages, treating vessels from 2 mm to 8 mm in diameter with a single device. Includes 5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere driveshaft options, pneumatic and electric-powered user handles, and a control module with tubing set.
- FreedomFlow Peripheral Guidewire Stainless steel core-to-tip peripheral guidewire with fixed distal-spring coil and silicone coating on the distal 200 cm. Designed to provide exceptional support for diagnostic and therapeutic devices used in treating plaque blockages in arteries both above and below the knee. The 0.014-inch core-to-tip design delivers superior torque transmission and precise control, enabling delivery of multiple interventional devices on a single guidewire.
Quantifiable outcome
- Treats vessels from 2mm in the ankle to 8mm in the hip with a single device
- +2 more outcomes
Companies that use Cardio Flow
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Cardio Flow technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Cardio Flow partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered key.
- Cardiovascular Institute of the South (CIS)keyCIS performed the first commercial cases of the FreedomFlow Orbital Atherectomy Platform. Drs. Craig Walker, Pradeep Nair, and McCall Walker conducted the initial procedures on patients with complex arterial anatomy, multiple blockages, and extensive calcium including chronic total occlusions.
- Advanced Cardiac & Vascular Centers for Amputation PreventionkeyDr. Jihad Mustapha, Director and Chief Medical Officer of Cardio Flow, is also President and CEO of Advanced Cardiac & Vascular Centers for Amputation Prevention. The centers serve as a key clinical site for FreedomFlow device testing and the first commercial case with the peripheral guidewire was performed there by Dr. Mustapha.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Cardio Flow competitors and assessment
Company assessmentDirect peers
- Avinger: Small-cap developer of lumivascular (OCT-guided) directional atherectomy (Pantheris, Tigereye) for PAD. Closely comparable in size, stage, and product focus to Cardio Flow, with similar U.S. sales channel.
- Penumbra: Makes the Indigo CAT RX aspiration system and Lightning Bolt/Storm peripheral thrombectomy portfolio - an emerging direct competitor in the PAD/CLTI interventional space where Cardio Flow also operates.
- Cardiovascular Systems (CSI): CSI pioneered orbital atherectomy with the Diamondback 360 and was acquired by Abbott in 2023. Cardio Flow's founders (Petrucci, Kallok) co-founded and led CSI, and FreedomFlow is the spiritual successor using a similar orbital mechanism - the closest possible direct peer.
- Surmodics: Develops and commercializes peripheral vascular intervention products including drug-coated balloons and the Sublime guidewire line. Targets the same cath lab, ASC, and OBL sites of care as FreedomFlow.
Broad incumbents
- AngioDynamics: Sells the Auryon atherectomy system (laser-based, acquired from Eximo Medical) within a broader vascular access and oncology portfolio. Direct competitor in peripheral atherectomy, particularly for below-the-knee lesions.
- Medtronic: Through the HawkOne directional atherectomy system (acquired from Covidien/eV3) Medtronic is a leading player in peripheral atherectomy. Offers a much broader portfolio of PAD devices, with global reach Cardio Flow lacks.
- Abbott Vascular: Acquired CSI in 2023 and now sells the Diamondback 360 orbital atherectomy line alongside a broad peripheral vascular portfolio (stents, balloons, closure). Competes head-to-head with FreedomFlow via the same mechanism Cardio Flow's founders originally commercialized.
- Boston Scientific: Sells the Rotacarett rotational atherectomy system as part of a large peripheral vascular franchise (angioplasty balloons, stents, thrombectomy). Competes with FreedomFlow in U.S. cath labs and OBLs treating PAD.
- Philips (Image-Guided Therapy): Markets laser atherectomy (formerly Spectranetics' Turbo-Elite and ExciLite) within a broad IGT/peripheral franchise. Competes with FreedomFlow in PAD/CLI procedures, especially where calcium modification is required.
Emerging players
- Inari Medical: Focuses on venous thromboembolism and peripheral thrombectomy (FlowTriever, ClotTriever), increasingly expanding into arterial PAD/CLTI procedures. Adjacent competitor for the same interventional cardiologist and vascular surgeon customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cardio Flow social profiles
Digital presenceCardio Flow compliance and trust
Trust signalCompliance2 records
Cardio Flow financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cardio Flow leadership team
Management profileNumber of profiles
Profiles6 records
Cardio Flow funding detail
Funding detailFunding overview
Funding rounds13 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cardio Flow M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cardio Flow
What does Cardio Flow do?
Cardio Flow develops and sells the FreedomFlow Orbital Atherectomy Platform, a catheter-based system that uses diamond-coated spheres in a spiral geometry leveraging angular momentum physics to treat peripheral artery disease in vessels from 2 mm to 8 mm in diameter. The platform includes multiple driveshaft configurations (5 Fr 3-sphere, 5 Fr 5-sphere, and 6 Fr 5-sphere), pneumatic and electric-powered user handles, a control module, and the complementary FreedomFlow Peripheral Guidewire, targeting hospitals, ambulatory surgery centers, and office-based labs.
Is Cardio Flow a public or private company?
Cardio Flow is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cardio Flow founded?
Cardio Flow was founded in 2014. It employs 11 to 50 people.
Where is Cardio Flow based?
Cardio Flow is headquartered in Saint Paul, United States, in the North America region.
How does Cardio Flow make money?
One revenue line is on record: freedomFlow Orbital Atherectomy Platform Sales.
Who are Cardio Flow's main competitors?
Direct peers on record are Avinger, Penumbra, Cardiovascular Systems (CSI) and Surmodics. Broad incumbents are AngioDynamics, Medtronic, Abbott Vascular, Boston Scientific and Philips (Image-Guided Therapy). Inari Medical is listed as an emerging player.
Does Cardio Flow have an API?
No public API is recorded for Cardio Flow.
What industry is Cardio Flow in?
Cardio Flow's product category is Peripheral Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy), with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart).